Santiago de Compostela, Spain – 30 July 2026 – Oncostellae, a clinical-stage biotechnology company developing innovative therapies for immune-mediated diseases, today announced its participation in the 26th Annual Biotech in Europe Forum (BEF), taking place on October 7–8, 2026, in Basel, Switzerland. The event, organized by Sachs Associates, is a leading European forum for biopharmaceutical partnering and investment, bringing together pharmaceutical and biotechnology companies, investors, and other life sciences stakeholders. The 2026 edition is expected to attract more than 650 delegates and feature more than 50 company presentations, alongside pre-arranged partnering meetings.
Oncostellae will use the forum to present its pipeline and engage with potential pharmaceutical partners and investors, with a particular focus on its lead asset OST-122, a gut-restricted JAK inhibitor in development for inflammatory bowel disease (IBD), including ulcerative colitis.
“Basel is one of Europe’s most important life sciences hubs, and the Biotech in Europe Forum provides an excellent opportunity to engage with pharmaceutical companies and investors as we advance OST-122 toward Phase 2b development,” said Guido Kurz, PhD, CEO of Oncostellae. “We look forward to discussing the potential of OST-122 and exploring strategic partnerships to accelerate its development for patients with IBD.”
The 26th Annual Biotech in Europe Forum will be held at the Mövenpick Hotel Basel on October 7–8, 2026, as part of Sachs Autumn Life Sciences Week.
About Oncostellae
Oncostellae is a clinical-stage biotechnology company focused on developing innovative small-molecule therapies for diseases with significant unmet medical needs. Its lead program, OST-122, is a gut-restricted JAK inhibitor designed to provide effective local treatment of inflammatory bowel disease while minimizing systemic exposure and associated toxicities. The company is advancing OST-122 toward a Phase 2b clinical trial in ulcerative colitis.
